应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02256 和誉-B
休市中 07-26 16:08:20
3.000
-0.010
-0.33%
最高
3.000
最低
2.940
成交量
9.90万
今开
2.990
昨收
3.010
日振幅
1.99%
总市值
20.59亿
流通市值
20.59亿
总股本
6.86亿
成交额
29.40万
换手率
0.01%
流通股本
6.86亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
和誉-B(02256.HK)8月12日举行董事会会议考虑及批准中期业绩
格隆汇资讯 · 07-26 16:51
和誉-B(02256.HK)8月12日举行董事会会议考虑及批准中期业绩
总收入约5亿元,和誉医药预计上半年扭亏为盈
新京报 · 07-12
总收入约5亿元,和誉医药预计上半年扭亏为盈
牵手默克入账近5亿 和誉医药扭亏为盈 上半年净赚超2亿
时代财经 · 07-11
牵手默克入账近5亿 和誉医药扭亏为盈 上半年净赚超2亿
【盈喜股】和誉(02256)涨逾5% 料中期扭亏为盈至多2.2亿元人民币
金吾财讯 · 07-11
【盈喜股】和誉(02256)涨逾5% 料中期扭亏为盈至多2.2亿元人民币
和誉-B早盘涨超5% 预计上半年利润超2亿元同比扭亏为盈
新浪港股 · 07-11
和誉-B早盘涨超5% 预计上半年利润超2亿元同比扭亏为盈
港股异动 | 和誉-B(02256)涨超5% 预计上半年利润超2亿元 同比扭亏为盈
智通财经 · 07-11
港股异动 | 和誉-B(02256)涨超5% 预计上半年利润超2亿元 同比扭亏为盈
和誉-B盘中异动 早盘股价大涨5.02%
自选股智能写手 · 07-11
和誉-B盘中异动 早盘股价大涨5.02%
和誉-B(02256)首次正面盈利、FIC/BIC管线爆发在即,真金白银回馈投资者提振信心
智通财经 · 07-11
和誉-B(02256)首次正面盈利、FIC/BIC管线爆发在即,真金白银回馈投资者提振信心
和誉-B预计上半年期内利润2亿元至2.2亿元 同比扭亏为盈
新浪港股 · 07-11
和誉-B预计上半年期内利润2亿元至2.2亿元 同比扭亏为盈
《盈喜》和誉(02256.HK)收入大增 上半年转赚至少2亿人民币
阿斯达克财经 · 07-11
《盈喜》和誉(02256.HK)收入大增 上半年转赚至少2亿人民币
和誉-B(02256)预计上半年期内利润2亿元至2.2亿元 同比扭亏为盈
智通财经网 · 07-10
和誉-B(02256)预计上半年期内利润2亿元至2.2亿元 同比扭亏为盈
和誉-B(02256)7月4日斥资64.65万港元回购20万股
智通财经 · 07-04
和誉-B(02256)7月4日斥资64.65万港元回购20万股
和誉(02256)已累计回购1583.3万股 涉资约4770.82万港元
金吾财讯 · 07-04
和誉(02256)已累计回购1583.3万股 涉资约4770.82万港元
和誉(02256.HK)累计回购1,583.3万股 涉资4,771万元
阿斯达克财经 · 07-04
和誉(02256.HK)累计回购1,583.3万股 涉资4,771万元
和誉-B(02256)累计购回1583.3万股股份 涉资约4770.82万港元
智通财经 · 07-04
和誉-B(02256)累计购回1583.3万股股份 涉资约4770.82万港元
和誉-B7月3日注销合计1583.3万股已回购股份
新浪港股 · 07-04
和誉-B7月3日注销合计1583.3万股已回购股份
和誉-B(02256)7月3日注销合计1583.3万股已回购股份
智通财经 · 07-03
和誉-B(02256)7月3日注销合计1583.3万股已回购股份
和誉-B7月2日斥资161.08万港元回购50万股
新浪港股 · 07-03
和誉-B7月2日斥资161.08万港元回购50万股
和誉-B(02256)7月2日斥资161.08万港元回购50万股
智通财经 · 07-02
和誉-B(02256)7月2日斥资161.08万港元回购50万股
和誉-B(02256)6月28日斥资164.47万港元回购50万股
智通财经 · 06-28
和誉-B(02256)6月28日斥资164.47万港元回购50万股
加载更多
公司概况
公司名称:
和誉-B
所属市场:
SEHK
上市日期:
--
主营业务:
和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4(FGFR4)抑制剂。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌(HCC)、尿路上皮癌(UC)及胃癌(GC)。
发行价格:
--
{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":3,"timestamp":1721981300027,"preClose":3.01,"halted":0,"volume":99000,"delay":0,"floatShares":686366350,"shares":686366350,"eps":-0.7171477,"marketStatus":"休市中","marketStatusCode":7,"change":-0.01,"latestTime":"07-26 16:08:20","open":2.99,"high":3,"low":2.94,"amount":293970,"amplitude":0.019934,"askPrice":3,"askSize":3000,"bidPrice":2.96,"bidSize":18000,"shortable":0,"etf":0,"ttmEps":-0.7171477124455478,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"listingDate":1634054400000,"adjPreClose":3.01,"openAndCloseTimeList":[[1721957400000,1721966400000],[1721970000000,1721980800000]],"volumeRatio":0.2847106908329152,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2454904273","title":"和誉-B(02256.HK)8月12日举行董事会会议考虑及批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2454904273","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454904273?lang=zh_cn&edition=full","pubTime":"2024-07-26 16:51","pubTimestamp":1721983881,"startTime":"0","endTime":"0","summary":"格隆汇7月26日丨和誉-B(02256.HK)宣布,公司将于2024年8月12日(星期一)举行董事会会议,藉以(其中包括)考虑及批准公司及其附属公司截至2024年6月30日止六个月之未经审计的中期业绩及其发布,以及考虑派发中期股息之建议(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726165136955ce37d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726165136955ce37d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2450228873","title":"总收入约5亿元,和誉医药预计上半年扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2450228873","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450228873?lang=zh_cn&edition=full","pubTime":"2024-07-12 12:24","pubTimestamp":1720758299,"startTime":"0","endTime":"0","summary":"新京报讯(记者张兆慧)7月11日,和誉医药发布2024年度上半年业绩预告,预计报告期内实现总收入约为4.97亿元,实现扭亏为盈。报告期内溢利约为2亿元-2.2亿元,首次实现半年度盈利。和誉医药称,预期收入增加及扭亏为盈主要源于Pimicotinib(ABSK021)的授权协议及默克公司的7000万美元(4.97亿人民币)首付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407123129597444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407123129597444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02256","09939","BK1161","BK1515","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2450351438","title":"牵手默克入账近5亿 和誉医药扭亏为盈 上半年净赚超2亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2450351438","media":"时代财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450351438?lang=zh_cn&edition=full","pubTime":"2024-07-11 20:07","pubTimestamp":1720699658,"startTime":"0","endTime":"0","summary":"又一港股18A创新药企扭亏为盈。7月10号晚间,和誉医药(02256.HK)发布正面盈利预告,公司预期今年上半年度总收入约为4.97亿元,实现扭亏为盈,上年同期为亏损2.09亿元;预期今年上半年录得期内溢利约2.0亿~2.2亿元,首次实现半年度盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407113128806492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B2B36J28.USD","LU2488822045.USD","09939","BK1515","IE00BFTCPJ56.SGD","LU0266013472.USD","LU0211331839.USD","LU0985320562.USD","LU0320765489.SGD","LU1934455194.USD","LU1061106388.HKD","BK4516","BK4534","LU0238689110.USD","LU1934455277.USD","LU1917777945.USD","LU0234572021.USD","LU1093756325.SGD","LU0265550946.USD","IE000M9KFDE8.USD","BK4559","IE0002141913.USD","IE0009355771.USD","LU1941712264.USD","IE00B4R5TH58.HKD","LU0861579265.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","BK4007","BK4550","LU1974910355.USD","LU1116320901.HKD","LU0070302665.USD","LU1066051498.USD","LU1066053197.SGD","BK4585","LU0965508806.USD","02256","LU1430594728.SGD","LU1066051225.USD","MRK","BK1161","LU1989772840.SGD","IE00BN8TJ469.HKD","LU1116320737.USD","BK4533","LU1934455863.HKD","LU0965509101.SGD","LU0965509010.AUD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2450805699","title":"【盈喜股】和誉(02256)涨逾5% 料中期扭亏为盈至多2.2亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2450805699","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450805699?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:14","pubTimestamp":1720667695,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)发盈喜,带动股价反弹,截至发稿,报3.15港元,涨5.35%,成交额248.65万港元。该股此前录得4连阴。据盈喜公告,预期截至2024年6月30日止六个月的总收入约为4.97亿元人民币,较上年同期约1900万元增加4.78亿元人民币;预期期内利润2亿-2.2亿元人民币,上年同期为亏损2.09亿元人民币。公告指,除了透过提高业务营运效率来改善成本控制外,预计总收入的增长及扭亏为盈亦主要归因于pimicotinib (ABSK021)的对外许可协议及与默克公司的首付款项7000万美(折合4.97亿元人民币),对中期收入作出重大贡献。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940200","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2450705368","title":"和誉-B早盘涨超5% 预计上半年利润超2亿元同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2450705368","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450705368?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:28","pubTimestamp":1720664915,"startTime":"0","endTime":"0","summary":"和誉-B(02256)早盘上涨5.02%,现报3.14港元,成交额178.74万港元。\n 和誉发布盈喜,预计截至2024年6月30日止6个月的总收入约为人民币4.97亿元,相比上年同期的1900万元同比取得大幅增长;预计期内取得利润为2亿元至2.2亿元,同比扭亏为盈。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-11/doc-incctqvf1951694.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-11/doc-incctqvf1951694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2450587758","title":"港股异动 | 和誉-B(02256)涨超5% 预计上半年利润超2亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2450587758","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450587758?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:11","pubTimestamp":1720663869,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和誉-B(02256)涨超5%,截至发稿,涨5.02%,报3.14港元,成交额141.29万港元。消息面上,和誉发布盈喜,预计截至2024年6月30日止6个月的总收入约为人民币4.97亿元,相比上年同期的1900万元同比取得大幅增长;预计期内取得利润为2亿元至2.2亿元,同比扭亏为盈。除了通过提高业务营运效率来改善成本控制外,还受惠于pimicotinib(ABSK021)的对外许可协议及与默克公司的首付款项7000万美元(人民币4.97亿元)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","BK1161","02256","HSTECH","HSCEI","07226","LU2488822045.USD"],"gpt_icon":0},{"id":"2450787252","title":"和誉-B盘中异动 早盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450787252","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450787252?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:03","pubTimestamp":1720663384,"startTime":"0","endTime":"0","summary":"2024年07月11日早盘10时03分,和誉-B股票出现异动,股价大幅上涨5.02%。和誉-B股票所在的生物技术行业中,整体涨幅为0.93%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。此次和誉宣布回购股票注销,正是其务实履行1亿港元注销回购计划,以“真金白银”回馈股东的重要操作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711100305af91ba05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711100305af91ba05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2450670876","title":"和誉-B(02256)首次正面盈利、FIC/BIC管线爆发在即,真金白银回馈投资者提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2450670876","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450670876?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:07","pubTimestamp":1720660065,"startTime":"0","endTime":"0","summary":"然而和誉-B仅用了3个年头便实现了这一目标。在创新研发与现金流加码的同时,和誉还宣布通过回购股票并注销来进一步提振市场信心。相较市面上仅回购的模式,注销股份的本质在于以“真金白银”回馈投资者,向市场传递积极信号。此次和誉宣布回购股票注销,正是其务实履行1亿港元注销回购计划,以“真金白银”回馈股东的重要操作。其中依帕戈替尼220mg BID联用阿替利珠队列在FGF19过表达患者中ORR达50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2450878649","title":"和誉-B预计上半年期内利润2亿元至2.2亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2450878649","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450878649?lang=zh_cn&edition=full","pubTime":"2024-07-11 08:07","pubTimestamp":1720656451,"startTime":"0","endTime":"0","summary":"和誉-B发布公告,基于对集团截至2024年6月30日止6个月的未经审核管理账目的初步审阅,集团于截至2024年6月30日止6个月的总收入预计约为人民币4.97亿元,较截至2023年6月30日止6个月的约人民币1900万元增加人民币4.78亿元;及集团于截至2024年6月30日止6个月预计取得人民币2亿元至人民币2.2亿元的期内利润,而截至2023年6月30日止6个月的期内亏损约为人民币2.09亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-11/doc-incctkpc8683425.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-11/doc-incctkpc8683425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2450284592","title":"《盈喜》和誉(02256.HK)收入大增 上半年转赚至少2亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2450284592","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450284592?lang=zh_cn&edition=full","pubTime":"2024-07-11 01:21","pubTimestamp":1720632060,"startTime":"0","endTime":"0","summary":"和誉-B(02256.HK) 发盈喜,与上年同期遨损2.09亿人民币相比,预计6月止六个月利润介乎2亿至2.2亿人民币;总收入预计由上年同期1,900万人民币大增至4.97亿人民币。除了改善成本控制外,亦受惠pimicotinib(ABSK021)的对外许可协议及与默克公司首付款项7,000万美元对收入作出重大贡献。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/03/12末期业绩无派息2023/08/15中期业绩无派息2023/03/15末期业绩无派息 2022/08/22中期业绩无派息 AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211028115122482_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211028115122482_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362787/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2450894998","title":"和誉-B(02256)预计上半年期内利润2亿元至2.2亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2450894998","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450894998?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:03","pubTimestamp":1720613036,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B 发布公告,基于对集团截至2024年6月30日止6个月的未经审核管理账目的初步审阅,集团于截至2024年6月30日止6个月的总收入预计约为人民币4.97亿元,较截至2023年6月30日止6个月的约人民币1900万元增加人民币4.78亿元;及集团于截至2024年6月30日止6个月预计取得人民币2亿元至人民币2.2亿元的期内利润,而截至2023年6月30日止6个月的期内亏损约为人民币2.09亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2448668428","title":"和誉-B(02256)7月4日斥资64.65万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448668428","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448668428?lang=zh_cn&edition=full","pubTime":"2024-07-04 21:03","pubTimestamp":1720098237,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,于2024年7月4日斥资64.65万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161"],"gpt_icon":0},{"id":"2448146860","title":"和誉(02256)已累计回购1583.3万股 涉资约4770.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448146860","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448146860?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:49","pubTimestamp":1720054158,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)发布公告,公司截至2024年6月17日已累计回购1583.3万股,占比已发行股份总数的2.25%,每股购回价格约2.72港元至3.41港元,涉资约4770.82万港元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200915/Yzc3ZjgxMDAwMDkzNTkwODc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/Yzc3ZjgxMDAwMDkzNTkwODc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256","BK1161"],"gpt_icon":0},{"id":"2448457125","title":"和誉(02256.HK)累计回购1,583.3万股 涉资4,771万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448457125","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448457125?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:22","pubTimestamp":1720052520,"startTime":"0","endTime":"0","summary":"和誉公布,根据购回股份授权,截至6月17日公司已累计购回1,583.3万股股份,占比已发行股份总数的2.25%,已购回股份已于昨日全部注销,涉资约4,770.82万元,每股购回价格约2.72至3.41元。公司用于购回股份的资金来自其自有财务资源,并非来自股份于联交所上市的所得款项。公司认为,目前股份的交易价格并未反映其内在价值,而购回股份计划的进行将提升股份的价值,从而增加股东的回报。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211028115122482_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211028115122482_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361229/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02256"],"gpt_icon":0},{"id":"2448457594","title":"和誉-B(02256)累计购回1583.3万股股份 涉资约4770.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448457594","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448457594?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:18","pubTimestamp":1720052283,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B 发布公告,根据购回股份授权,截至2024年6月17日,公司已累计购回1583.3万股股份,占比已发行股份总数的2.25%,已购回股份已于2024年7月3日全部注销,涉资约4770.82万港元,每股购回价格约2.72港元至3.41港元。购回股份乃根据上市规则及公司须遵守的所有适用法律法规进行。在遵守合规规定的前提下及从维持公司市值的角度,公司可能进一步购回股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161"],"gpt_icon":0},{"id":"2448454264","title":"和誉-B7月3日注销合计1583.3万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448454264","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448454264?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:02","pubTimestamp":1720051345,"startTime":"0","endTime":"0","summary":"和誉-B(02256)发布公告,于2024年7月3日注销合计1583.3万股已回购股份。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-04/doc-incaxnrp6053879.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-04/doc-incaxnrp6053879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","02256"],"gpt_icon":0},{"id":"2448316107","title":"和誉-B(02256)7月3日注销合计1583.3万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448316107","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448316107?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:50","pubTimestamp":1720011018,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,于2024年7月3日注销合计1583.3万股已回购股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161"],"gpt_icon":0},{"id":"2448116748","title":"和誉-B7月2日斥资161.08万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448116748","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448116748?lang=zh_cn&edition=full","pubTime":"2024-07-03 08:06","pubTimestamp":1719965197,"startTime":"0","endTime":"0","summary":"和誉-B(02256)发布公告,于2024年7月2日,该公司斥资161.08万港元回购50万股,每股回购价为3.17-3.27港元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-03/doc-incavckr7045699.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-03/doc-incavckr7045699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","02256"],"gpt_icon":0},{"id":"2448315182","title":"和誉-B(02256)7月2日斥资161.08万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448315182","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448315182?lang=zh_cn&edition=full","pubTime":"2024-07-02 21:10","pubTimestamp":1719925815,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,于2024年7月2日,该公司斥资161.08万港元回购50万股,每股回购价为3.17-3.27港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161"],"gpt_icon":0},{"id":"2446507713","title":"和誉-B(02256)6月28日斥资164.47万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446507713","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446507713?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:13","pubTimestamp":1719580382,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,于2024年6月28日斥资164.47万港元回购50万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.1176},{"period":"3month","weight":-0.0854},{"period":"6month","weight":0.1765},{"period":"1year","weight":0.083},{"period":"ytd","weight":-0.1781}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0357},{"period":"6month","weight":0.067},{"period":"1year","weight":-0.1333},{"period":"ytd","weight":-0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4(FGFR4)抑制剂。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌(HCC)、尿路上皮癌(UC)及胃癌(GC)。","exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}